# Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients

> **NCT04002323** · — · COMPLETED · sponsor: **University Hospital Virgen de las Nieves** · enrollment: 88 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Dolutegravir 50mg Tab
- **DRUG:** Lamivudine 300 mg

## Key facts

- **NCT ID:** NCT04002323
- **Lead sponsor:** University Hospital Virgen de las Nieves
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-07
- **Primary completion:** 2021-02-28
- **Final completion:** 2022-03-31
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04002323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04002323, "Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04002323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*